RECOVERY: A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions of Native Coronary Artery

Trial Profile

RECOVERY: A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions of Native Coronary Artery

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Anti-CD34 monoclonal antibody/sirolimus (Primary)
  • Indications Coronary arteriosclerosis
  • Focus Therapeutic Use
  • Acronyms RECOVERY
  • Sponsors OrbusNeich
  • Most Recent Events

    • 05 Oct 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Nov 2017.
    • 22 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 08 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top